top of page
Latest Updates
September 17, 2025
Numiera Therapeutics will share our drug development program with investors focused on oncology therapeutics at RESI in Boston, MA.
September 11, 2025
Numiera Therapeutics CEO Dr. Izi Stoll is named WINNER of the TiE Colorado Pitch Competition. We're going to India for the TiE Global Pitch Competition!
July 17, 2025
Numiera Therapeutics presents safety and efficacy data on their lead molecule at the Silicon Valley Cancer Tech Conference in Palo Alto, CA.
May 13, 2025
Numiera Therapeutics CEO Dr. Izi Stoll is awarded best startup pitch at the BioNJ partnering meeting at Liberty Science Center in Jersey City NJ.
Apr 3, 2025
Numiera Therapeutics CEO Dr. Izi Stoll is honored as a top innovator at Venture Summit West in Mountain View CA.
Mar 30, 2025
Numiera Therapeutics announces it has hired Dr. Megan Halloran to support communications between the company and its stakeholders.
Feb 21, 2025
Numiera Therapeutics announces its investors receive a 25% tax credit from Colorado's Office of Economic Development and International Trade.
Jan 10, 2025
Numiera Therapeutics announces it has been granted Orphan Drug Designation to use etomoxir in the treatment of patients with malignant glioma.
Nov 21, 2024
Numiera Therapeutics announces a competitively-awarded grant of $250,000 from Colorado's Office of Economic Development and International Trade.
Aug 21, 2024
Numiera Therapeutics announces a significant expansion of the leadership team to include pharma experts Gordon Beck and Karl Nicholls.
Patient Advocacy
GBM5 Drug Development Summit
Meeting with the team at End Brain Cancer
NBTS Annual Walk at Sloan Lake, CO
Working with our JP Morgan Chase banking team to raise funds for the National Brain Tumor Society
Oligo Nation Gala in Denver, CO
Attending a fundraiser to support patients with oligodendroglioma
ABTA Annual Meeting in Schaumburg, IL
Working with the American Brain Tumor Association to coordinate clinical trials for patients with brain tumors
bottom of page